In view of the fact, that all the mutations were detected after the start of the therapy, expansion of BCR/ABL gene mutation in CML can be considered to be time dependent and dependent on pressure exerted by tyrosine kinase inhibitor. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.